Mass index; FBG: fasting blood glucose; eGFR: estimated glomerular filtration rate; ALT: alanine transaminase; AST: aspartate transaminase; CHD: coronary heart disease. One-way ANOVA and Kruskal-Wallis test were applied for statistical analyses.expression of platelet PAC-1 and CD62p. The statistical application package Stata 11.0 (Stata Corp. LP, USA) was utilized for the analysis.the groups. The lipid profiles of atorvastatin-treated sufferers are shown in Table 2. Entire blood flow cytometry The data showed improved platelet surface expression of CD62p (P-selectin) and PAC-1 (GPIIb/IIIa) in the HNC group compared with all the NOMC group (P=0.004 and P=0.014). Moreover, the expressions of platelet markers CD62p and PAC-1 were greater within the HLC group than in the HNC group (P=0.004 and P=0.026; Table three and Figure 1). The platelet activation markers CD62p and PAC-1 decreased considerably right after MEM Non-essential Amino Acid Solution (100��) MedChemExpress atorvastatin therapy (Table three). The parameter baseline of two months was obtained to analyzeResultsCharacteristics of participants A total of 48 patients with high levels of LDL-C had been recruited: 25 individuals inside the HNC group and 23 patients in the HLC group. The NOMC group consisted of 35 healthful volunteers. The relevant biochemical and hematological final results are reported in Table 1. There were no differences in age, IFN-gamma Protein Gene ID gender, physique mass index, or cardiovascular threat components (hypertension, diabetes mellitus, smoking history) betweenTable 2. Lipid profiles of atorvastatin-treated patients at baseline and following 1 and 2 months of therapy. TC (mM) Baseline HNC (n=25) HLC (n=23) 1 month HNC (n=25) HLC (n=23) 2 months HNC (n=25) HLC (n=23) NOMC (n=35) TG (mM) LDL-C (mM) HDL-C (mM)6.67 ?0.66 6.60 ?0.54 four.86 ?0.84### 4.64 ?0.92### 4.79 ?0.71### 4.78 ?0.46### 4.12 ?0.1.69 ?0.29 1.66 ?0.42 1.39 ?0.47## 1.39 ?0.39# 1.75 ?0.46 1.60 ?0.36 1.64 ?0.4.41 ?0.20 4.47 ?0.22 two.53 ?0.80### 2.29 ?0.63### two.42 ?0.40### two.60 ?0.41### 1.78 ?0.1.13 ?0.14 0.88 ?0.10nnn 1.11 ?0.23 0.91 ?0.20 1.00 ?0.19# 0.88 ?0.20 1.15 ?0.Data are reported as means D. TC: total cholesterol; TG: triglycerides; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; HNC: higher levels of LDL-C combined with regular levels of HDL-C; HLC: high levels of LDL-C combined with low levels of HDL-C; NOMC: normocholesterolemic. P,0.001 vs manage (NOMC); # P,0.05 vs baseline; ## P,0.01 vs baseline; ### P,0.001 vs baseline; nnn P,0.001 vs HNC. One-way ANOVA, Kruskal-Wallis test, group t-test, Wilcoxon’s test, paired t-tests and matched-pairs signed-rank tests had been employed for statistical analyses.bjournal.brBraz J Med Biol Res 48(2)L.W. Chan et al.Table 3. Parameters of platelet CD62p and PAC-1 among HNC and HLC individuals and NOMC volunteers. Platelet CD62p ( ) HNC (n=25) Baseline 1 mo ATOR two mo ATOR Baseline-2 mo HLC (n=23) Baseline 1 mo ATOR 2 mo ATOR Baseline-2 mo NOMC (n=35) Platelet PAC-1 ( ) MPAG ( )1.62 1.53 0.88 0.74 two.60 1.19 1.51 1.04 0.?????????1.01 1.71 0.74## 1.12 1.19nn 1.43### 1.67##NS 1.92NS 0.four.21 three.57 1.36 two.85 5.90 four.03 2.33 3.57 2.?????????two.50 2.63 1.02### two.73 two.58n two.67# 1.57###n two.55NS two.31.54 29.61 26.85 4.70 37.15 28.21 26.18 10.97 29.?????????15.12 17.46 10.62 19.11 18.85 16.41 12.59# 21.59NS 17.HNC: higher levels of LDL-C combined with standard levels of HDL-C; HLC: high levels of LDL-C combined with low levels of HDL-C; NOMC: normocholesterolemic; mo: month; ATOR: atorvastatin; MPAG: maximal platelet aggregation. P,0.05 vs manage; P,0.01 vs control (NOMC); P,0.001 vs.